SG11201606413RA - Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient - Google Patents
Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredientInfo
- Publication number
- SG11201606413RA SG11201606413RA SG11201606413RA SG11201606413RA SG11201606413RA SG 11201606413R A SG11201606413R A SG 11201606413RA SG 11201606413R A SG11201606413R A SG 11201606413RA SG 11201606413R A SG11201606413R A SG 11201606413RA SG 11201606413R A SG11201606413R A SG 11201606413RA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- active ingredient
- carboxamide compound
- heterocyclic carboxamide
- diamino heterocyclic
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- -1 heterocyclic carboxamide compound Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014019226 | 2014-02-04 | ||
| PCT/JP2015/053018 WO2015119122A1 (ja) | 2014-02-04 | 2015-02-03 | ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201606413RA true SG11201606413RA (en) | 2016-09-29 |
Family
ID=53777926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606413RA SG11201606413RA (en) | 2014-02-04 | 2015-02-03 | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11045468B2 (ja) |
| EP (1) | EP3103453B1 (ja) |
| JP (1) | JP6390626B2 (ja) |
| KR (1) | KR102322338B1 (ja) |
| CN (3) | CN116509866A (ja) |
| AU (1) | AU2015215578B2 (ja) |
| BR (1) | BR112016017897A8 (ja) |
| CA (1) | CA2938818C (ja) |
| CY (1) | CY1122968T1 (ja) |
| DK (1) | DK3103453T3 (ja) |
| EA (1) | EA033304B1 (ja) |
| ES (1) | ES2788390T3 (ja) |
| HR (1) | HRP20200662T1 (ja) |
| HU (1) | HUE049437T2 (ja) |
| IL (1) | IL247077B (ja) |
| LT (1) | LT3103453T (ja) |
| ME (1) | ME03775B (ja) |
| MX (1) | MX363543B (ja) |
| MY (1) | MY193536A (ja) |
| PH (1) | PH12016501527A1 (ja) |
| PL (1) | PL3103453T3 (ja) |
| PT (1) | PT3103453T (ja) |
| RS (1) | RS60150B1 (ja) |
| SG (1) | SG11201606413RA (ja) |
| SI (1) | SI3103453T1 (ja) |
| TW (1) | TWI655945B (ja) |
| UA (1) | UA120607C2 (ja) |
| WO (1) | WO2015119122A1 (ja) |
| ZA (1) | ZA201605379B (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116509866A (zh) * | 2014-02-04 | 2023-08-01 | 安斯泰来制药株式会社 | 二氨基杂环甲酰胺化合物的用途 |
| FI3318259T3 (fi) | 2015-07-03 | 2023-03-20 | Astellas Pharma Inc | Stabiili farmaseuttinen koostumus annettavaksi suun kautta |
| EP3372231B1 (en) * | 2015-11-04 | 2021-09-15 | Astellas Pharma Inc. | Pharmaceutical composition for cancer immunotherapy purposes and/or immunostimulation purposes which contains diamino heterocyclic carboxamide compound as active ingredient |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JPWO2022220227A1 (ja) * | 2021-04-14 | 2022-10-20 | ||
| TW202340177A (zh) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | 作為 flt3抑制劑之吡嗪化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2715380A1 (en) * | 2008-02-12 | 2009-08-20 | The Brigham And Women's Hospital, Inc. | Fish assay for eml4 and alk fusion in lung cancer |
| WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| RS54552B1 (en) | 2009-05-08 | 2016-06-30 | Astellas Pharma Inc. | UNIT OF DIAMINO HETEROCYCLIC CARBOXAMIDE |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| RU2014121820A (ru) * | 2011-11-21 | 2015-12-27 | Иммьюноджен, Инк. | Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством |
| UA113204C2 (xx) | 2012-04-02 | 2016-12-26 | Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції | |
| HUE041499T2 (hu) * | 2012-11-21 | 2019-05-28 | Janssen Biotech Inc | Bispecifikus EGFR/C-MET-ellenanyagok |
| CN116509866A (zh) * | 2014-02-04 | 2023-08-01 | 安斯泰来制药株式会社 | 二氨基杂环甲酰胺化合物的用途 |
| WO2015127234A1 (en) | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| FI3318259T3 (fi) * | 2015-07-03 | 2023-03-20 | Astellas Pharma Inc | Stabiili farmaseuttinen koostumus annettavaksi suun kautta |
-
2015
- 2015-02-03 CN CN202310702543.7A patent/CN116509866A/zh active Pending
- 2015-02-03 UA UAA201609187A patent/UA120607C2/uk unknown
- 2015-02-03 CN CN202110880188.3A patent/CN113425727A/zh active Pending
- 2015-02-03 ME MEP-2020-77A patent/ME03775B/me unknown
- 2015-02-03 CN CN201580006772.9A patent/CN105939714A/zh active Pending
- 2015-02-03 RS RS20200432A patent/RS60150B1/sr unknown
- 2015-02-03 AU AU2015215578A patent/AU2015215578B2/en active Active
- 2015-02-03 BR BR112016017897A patent/BR112016017897A8/pt not_active Application Discontinuation
- 2015-02-03 MY MYPI2016702813A patent/MY193536A/en unknown
- 2015-02-03 SI SI201531179T patent/SI3103453T1/sl unknown
- 2015-02-03 EP EP15746276.3A patent/EP3103453B1/en active Active
- 2015-02-03 MX MX2016010134A patent/MX363543B/es unknown
- 2015-02-03 PT PT157462763T patent/PT3103453T/pt unknown
- 2015-02-03 EA EA201691570A patent/EA033304B1/ru not_active IP Right Cessation
- 2015-02-03 US US15/116,736 patent/US11045468B2/en active Active
- 2015-02-03 ES ES15746276T patent/ES2788390T3/es active Active
- 2015-02-03 LT LTEP15746276.3T patent/LT3103453T/lt unknown
- 2015-02-03 SG SG11201606413RA patent/SG11201606413RA/en unknown
- 2015-02-03 JP JP2015560991A patent/JP6390626B2/ja active Active
- 2015-02-03 DK DK15746276.3T patent/DK3103453T3/da active
- 2015-02-03 PL PL15746276T patent/PL3103453T3/pl unknown
- 2015-02-03 CA CA2938818A patent/CA2938818C/en active Active
- 2015-02-03 KR KR1020167022660A patent/KR102322338B1/ko active IP Right Grant
- 2015-02-03 WO PCT/JP2015/053018 patent/WO2015119122A1/ja active Application Filing
- 2015-02-03 HU HUE15746276A patent/HUE049437T2/hu unknown
- 2015-02-04 TW TW104103756A patent/TWI655945B/zh active
-
2016
- 2016-08-02 IL IL247077A patent/IL247077B/en active IP Right Grant
- 2016-08-03 PH PH12016501527A patent/PH12016501527A1/en unknown
- 2016-08-04 ZA ZA2016/05379A patent/ZA201605379B/en unknown
-
2020
- 2020-04-24 HR HRP20200662TT patent/HRP20200662T1/hr unknown
- 2020-04-28 CY CY20201100384T patent/CY1122968T1/el unknown
-
2021
- 2021-05-21 US US17/327,337 patent/US11925638B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1219432A1 (zh) | 以嘧啶化合物爲有效成分的醫藥組合物 | |
| IL247062A0 (en) | Heterocyclic compounds, their preparation and pharmaceutical preparations containing them | |
| ZA201605379B (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| IL253538A0 (en) | Heterocyclic compound and pharmaceutical compound containing it | |
| HK1254573A1 (zh) | 包含苯基氨基嘧啶衍生物的藥物組合物 | |
| PT3202759T (pt) | Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo | |
| IL304109A (en) | Pharmaceutical preparations containing spinamide | |
| HK1243927A1 (zh) | 含有茶皂醇衍生物作爲活性成分的組合物 | |
| HUE053974T2 (hu) | Szemészeti gyógyászati készítmény | |
| IL249010A0 (en) | A pharmaceutical preparation containing a pyrazine carboxamide compound as an active ingredient | |
| SG11201610636VA (en) | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor | |
| EP3372231A4 (en) | PHARMACEUTICAL COMPOSITION FOR ANTICANCER IMMUNOTHERAPY AND / OR FOR IMMUNOSTIMULATION, CONTAINING AS ACTIVE PRINCIPLE A HETEROCYCLIC DIAMINO CARBOXAMIDE COMPOUND | |
| IL252663A0 (en) | A pharmaceutical preparation containing an aromatic heterocyclic amide compound containing nitrogen as an active ingredient | |
| PT3424500T (pt) | Composição farmacêutica que compreende famitinib | |
| IL252664A0 (en) | A pharmaceutical preparation containing an aromatic heterocyclic amide compound containing nitrogen as an active ingredient | |
| ZA201803722B (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | |
| HUE058886T2 (hu) | Safinamidot tartalmazó gyógyászati készítmények |